Survival-Adjusted FEV1 and BMI Percentiles for Patients with Cystic Fibrosis before the Era of Triple CFTR Modulator Therapy in Germany

Dittrich A.S.a,b· Dumke M.c· Kapl F.c· Schneider P.b· Wege S.a,b· Gräber S.d,e,f· Stahl M.d,e,f· Herth F.J.a,b· Naehrlich L.g,h· Mall M.A.d,e,f· Sommburg O.b,i· German CF Registry

Author affiliations

aDepartment of Pneumology and Critical Care Medicine, Thoraxklinik at the University Hospital Heidelberg, Heidelberg, Germany
bTranslational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany
cStat-Up, Munich, Germany
dDepartment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
eBerlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany
fGerman Center for Lung Research (DZL), associated partner, Berlin, Germany
gDepartment of Pediatrics, Justus-Liebig-University, Giessen, Germany
hMukoviszidose Institut gGmbH (MI), Bonn, Germany
iDivision of Pediatric Pulmonology & Allergy and Cystic Fibrosis Center, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany

留言 (0)

沒有登入
gif